期刊文献+

MiRNA在阿尔茨海默症发病机制中的作用 被引量:4

Research progress of miRNA in the pathogenesis of Alzheimer’s disease
原文传递
导出
摘要 阿尔茨海默症(Alzheimer’s disease, AD)是一种常见的神经退行性疾病。近年来,AD发病率逐年增加,且常用的抗AD药物也只能改善中、轻度AD患者的症状,并不能预防、阻止和逆转AD的发展,该疾病严重影响了患者的生活质量。MiRNAs为新发现的一类具有调控人体多蛋白基因组学的非编码RNA,在生物体的生长发育、疾病的发生发展过程中起着非常重要的作用。越来越多的研究表明miRNAs与AD的发生、发展密切相关,故本文将miRNAs在AD中的作用作一综述,重点阐述miRNAs在AD发病机制中的调节作用,以及通过调节miRNAs发挥作用的天然产物和运动干预,以期为AD的治疗提供新的思路和方向。 Alzheimer’s disease(AD) is one of the common neurodegenerative diseases. In recent years, the incidence of AD has increased year by year, and the commonly used anti-AD drugs can only improve the symptoms of patients with moderate to mild AD, and can not prevent, stop or reverse the development of AD. The disease seriously affects the quality of patients’ life. MiRNAs are a newly indentified class of noncoding RNAs that regulate human polyprotein genomics, and play a key role in the growth and development of organisms and the occurrence and development of diseases. Increasing evidence show that miRNA is closely related to AD, thus this review illustrated the research of AD and miRNAs, focusing on the regulation of miRNAs in the pathogenesis of AD, miRNAs-related natural products as well as physical exercise intervention, in order to provide new ideas and directions for the treatment of AD.
作者 张蒙 寇现娟 ZHANG Meng;KOU Xianjuan(Graduate School,Wuhan Sports University,Wuhan 430079,China;College of Health Science,Wuhan Sports University,Hubei Key Laboratory of Sport Training and Monitoring,Wuhan 430079,China)
出处 《生命的化学》 CAS CSCD 2020年第9期1547-1557,共11页 Chemistry of Life
基金 国家自然科学基金项目(81601228)。
关键词 MIRNAS 阿尔茨海默症 发病机制 天然产物 运动干预 miRNAs Alzheimer’s disease pathogenesis natural products exercise intervention
  • 相关文献

参考文献11

二级参考文献91

  • 1赵绪韬,傅毅,董文心.β淀粉样蛋白靶向药物治疗阿尔茨海默病的研究进展[J].世界临床药物,2013,34(1):49-54. 被引量:7
  • 2徐静娟,姚茂君,许钢.二氢杨梅素抗氧化功能的研究[J].食品科学,2007,28(9):43-45. 被引量:28
  • 3Tam JH, Pasternak SH. Amyloid and Alzheimer's disease: inside and out[J]. Can J Neurol Sci,2012, 39(3) :286 -298.
  • 4Lozano R, Naghavi M, Foreman K, et al. Global and regional mortal- ity from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 [ J ]. Lancet, 2013, 380(9859) :2095 -2128.
  • 5Wang Q, Xu Y, Chen JC, et al. Stromal cell - derived factor 1 c- de- creases 13 - amyloid deposition in Alzheimer's disease mouse model [J]. Brain Res, 2012, 1459(1) :15 -26.
  • 6杜俊蓉,旷喜,陈娅姝,等.13K/AKT信号通路在藁本内酯治疗老年性痴呆有效性中的作用[J].中国药理学与毒理学杂志,2012,26(3):421-422.
  • 7Borgegard T, Gustavsson S, Nilsson C, et al. Alzheimer's disease: presenilin 2 - sparing 5' - secretase inhibition is a tolerable Aβ peptide - lowering strategy [ .l ]..1 Neurosci, 2012, 32 ( 48 ) : 17297 - 17305.
  • 8Hamilton A, Holscher C. The effect of ageing on neurogenesis and ox- idative stress in the APP(swe)/PSI (deltaE9) mouse model of Alzhe- imer's disease[ Jl. Brain Res, 2012, 1449 ( 1 ) :83 - 93.
  • 9Chow VW, Mattson MP, Wong PC, et al. An overview of APP pro- cessing enzymes and products [ J]. Neuromolecular Med, 2010, 12 (1):1 -12.
  • 10Nemirovsky A, Shapiro J, Baron R, et al. Active A13 vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with AI342 - driven pathology [ J ]. J Neuroimmunol, 2012, 247 ( 1 -2) :95 -99.

共引文献138

同被引文献76

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部